Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome

Abstract

oBJectIVe: there is a need for a simple and accurate method for the assessment of cardiovascular risk in polycystic ovary syndrome (Pcos). Lipid accumulation product (LAP) is based on the assessment of waist circumference and serum triglycerides that yield an estimation of lipid overaccumulation. we aimed to determine whether LAP is associated with metabolic syndrome (Mets) in caucasian women with Pcos. desIGn: we studied 222 women with Pcos who were diagnosed using the Rotterdam criteria. In all the subjects and controls, LAP was determined and the Mets was assessed using three different international criteria, nceP-AtP III, Idf, and JIs. Roc curve and logistic regression analyses were performed to determine and analyze associations with the Mets. ResuLts: In the study population the prevalence of Mets was 16.2-19.4%. the cut-off value of 25.9 determined that LAP has the strongest association with Mets whichever international criteria are used, followed by HdL (nceP-AtP III and JIs) and glucose (Idf). concLusIons: LAP is used as an independent clinical indicator for Mets in our Pcos women of caucasian origin. the high diagnostic accuracy of LAP is superseding the need for the use of multiple clinical indicators for the assessment of lipid accumulation as a prerequisite for diagnosis of metabolic and cardiovascular diseases in Pcos women.

Lipid accumulation product as a marker of cardiometabolic susceptibility in women with different phenotypes of polycystic ovary syndrome

“…marker of IR, MetS, cardiovascular risk and mortality in non-PCOS populations (13,28,51) as well as in PCOS population (15,16,52). Previously we showed that LAP was the strongest predictor of MetS defined by three different international criteria in Caucasian women with PCOS (19). In the present study, we have confirmed that LAP is an independent predictor of MetS in each PCOS phenotype.…”

“…Recently, we have shown a strong association between LAP and MetS in Caucasian PCOS population. Moreover, LAP had the highest diagnostic accuracy in comparison to other MetS determinants regardless of which MetS definition was used (NCEP-ATP III, IDF or JIS) (19). Since there is emerging evidence of variability of cardiometabolic risks in different PCOS phenotypes (8,20), the aim of this study was to evaluate the metabolic characteristics and prevalence of MetS, as well as to analyze the ability of LAP to predict MetS in different phenotypes of women with PCOS.…”

Increased serum fetuin-B concentration is associated with HOMA-β and indices of liver steatosis in women with polycystic ovary syndrome: a pilot study

“…In our study, we also observed a relationship between indices of liver steatosis and percent of body fat, HOMA-IR and HDL cholesterol in PCOS women. Similarly, in the previous study of the aforementioned authors, a correlation between LAP and the presence of insulin resistance, metabolic syndrome and impaired glucose tolerance in PCOS women has been shown (5, 26). All of these findings might have a therapeutic implication.…”

Lipid accumulation product independently correlate with hepatic steatosis quantified by controlled attenuation parameter in women with polycystic ovary syndrome

“…The three combined metabolic indices LAP, VAI, and TyG have been introduced as indicators of visceral adipose function and IR (15), which also could discriminate prediabetes and diabetes (17). In women with PCOS, LAP, a newly developed biomarker which mainly reflects the abdominal obesity, is associated with IR and MetS in women with PCOS (21,26,27). Polyzos et al (28) reported that LAP level is higher in PCOS patients with MetS than that in those without.…”